Organization | GROUPE ONCOLOGIE RADIOTHERAPIE TETE ET COU

GROUPE ONCOLOGIE RADIOTHERAPIE TETE ET COU Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3

Founded: Tours France (1999)

Organization Overview

First Clinical Trial

2008

NCT00609284

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

CorTec GmbH | GORTEC | GORTEC President

Active Ingredients

Drugs in Phase 3 Trials (4)

carboplatin (paraplatin) (1 trial)

cetuximab (erbitux) (3 trials)

fluorouracil (efudex) (3 trials)

pembrolizumab (keytruda) (2 trials)

Drugs in Phase 2 Trials (3)

cisplatin (platinol) (3 trials)

docetaxel (taxotere) (3 trials)

sargramostim (leukine) (1 trial)

Drugs in Phase 1 Trials (1)

afatinib (gilotrif) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Carcinoma (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Neoplasm Metastasis (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 6
# of Trial APIs: 8